

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2025

	30.09.2025	31.12.2024
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	32 362	33 304
Intangible assets	3 638	2 836
Investments in subsidiaries	69	69
Trade receivables	5 403	5 403
Total non-current assets	42 472	41 612
Current assets		
Inventories	16 742	15 862
Trade and other receivables	74 386	70 822
Current corporate income tax	-	129
Cash and cash equivalents	310	79
Total current assets	91 438	86 892
Total assets	133 910	128 504
LIABILITIES		
Equity		
Share capital	95 900	91 800
Reserves	13 549	13 147
Retained earnings	6 598	4 552
Total	116 047	109 449
Non-current liabilities		
Long-term loans	1 146	675
Deferred tax liabilities	1 198	1 198
Retirement benefit obligations	268	268
Total non-current liabilities	2 612	2 141
Current liabilities		
Trade and other liabilities	3 896	6 337
Short-term loans	9 778	9 784
Current portion of long-term loans	922	670
Other tax liabilities	655	123
Total current liabilities	15 251	16 914
Total liabilities	17 863	19 055
Total equity and liabilities	133 910	128 504

Date of preparation: 28.10.2025
Sofia

Prepared by:.....
/Ts. Pandeva/


Executive Director:.....
/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2025

	30.09.2025	30.09.2024
	BGN'000	BGN'000
Revenue	47 984	40 414
Other income	2	182
Total income	47 986	40 596
Carrying amount of goods sold	(2 260)	(1 953)
Changes in inventories of finished products and work in progress	14	318
Materials and services	(27 826)	(24 712)
Personnel expenses	(7 868)	(6 664)
Depreciation / amortisation expenses	(2 129)	(1 877)
Other expenses	(470)	(434)
Finance income	78	40
Finance costs	(432)	(550)
Total expenses	(40 893)	(35 832)
Profit before taxation	7 093	4 764
Corporate income tax expense	(495)	(420)
Profit/Loss for the period	6 598	4 344
Total comprehensive income for the period	6 598	4 344
Earnings per share / in BGN per 1 share /	0.07	0.05

Date of preparation: 28.10.2025
Sofia


Prepared by:.....
/Ts. Pandeva/


Executive Director:.....
/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2025

	30.09.2025	30.09.2024
	BGN'000	BGN'000
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	35 433	30 227
Payments to suppliers of materials, goods and services	(19 061)	(15 642)
Payments to personnel	(8 020)	(6 832)
Foreign currency exchange gains/losses	(21)	(26)
Payments of interest and dividends	(366)	(408)
Other proceeds / payments	(6 042)	(4 704)
Net cash flows	1 923	2 615
Cash flows from investing activities		
Payments on non-current assets acquired	(975)	(1 687)
Other post/payments for investment activity		(50)
Net cash flows	(975)	(1 737)
Cash flows from financial activities		
Proceeds from loans	341	438
Payments on loans	(343)	(446)
Payment of interest, dividends	(323)	(428)
Payments on finance lease	(392)	(391)
Net cash flows	(717)	(827)
Change in cash and cash equivalents	231	51
Cash and cash equivalents at the beginning of the period	79	60
Cash and cash equivalents at the end of the period	310	111

Date of preparation: 28.10.2025

Sofia

Prepared by:.....
 /Ts. Pandeva/

Executive
 Director:.....
 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2025

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2024	84 500	4 369	8 431	7 707	105 007
Profit/loss for the period				4 492	4 492
Other comprehensive income		(50)			(50)
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		(50)		4 492	4 442
Issue of shares by the owners	7 300		347	(7 647)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period	7 300		347	(7 647)	
Balance as of 31.12.2024	91 800	4 319	8 778	4 552	109 449
Balance as of 01.01.2025	91 800	4 319	8 778	4 552	109 449
Profit/loss for the period				6 598	6 598
Other comprehensive income					
Total comprehensive income				6 598	6 598
Issue of shares by the owners	4 100		452	(4 552)	
Total amount of income and expenses recognised during the period					
Balance as of 30.09.2025	95 900	4 319	9 230	6 598	116 047

Date of preparation: 28.10.2025
Sofia

Prepared by:.....
/Ts. Pandeva/

Executive Director:.....
/B. Georgiev /